Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M
Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Md, USA.
Arch Intern Med. 1997;157(15):1651-6. doi: 10.1001/archinte.157.15.1651.
Sporadic single case reports linking glucocorticoidlike activity to megestrol acetate have been reported in the literature. These findings have important implications for patient care. Adverse drug experience reports to the US Food and Drug Administration from 1984 through 1996 and a MEDLINE search of the literature from 1984 through 1996 provided the case reports. Five cases of Cushing syndrome, 12 cases of new-onset diabetes, and 16 cases of adrenal insufficiency were identified in association with megestrol therapy. Twelve cases in which preexisting diabetes was exacerbated and 17 cases of possible adrenal insufficiency were identified. Therapy with megestrol can result in clinical manifestations of glucocorticoidlike activity, including Cushing syndrome, diabetes, and adrenal insufficiency. Clinicians need to be aware of this association as these complications can be life-threatening if not recognized.
文献中已有散在的个案报道将醋酸甲地孕酮与糖皮质激素样活性联系起来。这些发现对患者护理具有重要意义。1984年至1996年向美国食品药品监督管理局提交的药品不良反应报告以及1984年至1996年对文献进行的医学文献数据库检索提供了这些病例报告。在甲地孕酮治疗相关病例中，确认有5例库欣综合征、12例新发糖尿病和16例肾上腺功能不全。还确认有12例既往糖尿病病情加重以及17例可能的肾上腺功能不全。甲地孕酮治疗可导致糖皮质激素样活性的临床表现，包括库欣综合征、糖尿病和肾上腺功能不全。临床医生需要了解这种关联，因为如果未识别出这些并发症，可能会危及生命。
